How does Rydapt actually work inside my body to fight cancer?
Rydapt (midostaurin) blocks FLT3 and KIT kinase proteins that tell cancer cells to grow and divide. By shutting down these growth signals, Rydapt slows or stops leukemia cell multiplication, giving your immune system a better chance to control the disease [1].
Rydapt is a small-molecule kinase inhibitor that targets FLT3-ITD (internal tandem duplication) mutations found in about 25–30% of acute myeloid leukemia (AML) cases. Clinical trials show that adding Rydapt to standard chemotherapy improves overall survival by roughly 15–20% compared to chemotherapy alone [1]. The FDA approved it based on these survival gains in newly diagnosed AML patients with FLT3 mutations.
Inside your leukemia cells, FLT3 and KIT are like broken 'on switches' that keep telling cells to divide nonstop. Rydapt fits into the active pocket of these kinase enzymes and jams the switch in the 'off' position. This stops the cancer cells from receiving the growth signal, so they either die or stop multiplying—while your normal blood cells are less affected because they don't rely as heavily on these same pathways [1].
You take Rydapt twice daily with food because the liquid-filled capsule absorbs better when there's fat in your stomach. Your liver (via CYP3A4 enzymes) breaks it down, and your kidneys excrete it over 24–48 hours. If you're also taking a strong CYP3A4 inhibitor like ketoconazole, Rydapt levels can build up dangerously—so your oncologist may cut your dose in half to keep you safe [1].
Ask your oncologist: 'Did my leukemia cells test positive for FLT3 mutations?' If yes, Rydapt is a targeted fit. If no, discuss whether Rydapt is still part of your protocol or if another kinase inhibitor might work better for your specific mutation profile.